Myocardial overexpression of ANKRD1 causes sinus venosus defects and progressive diastolic dysfunction.


Journal

Cardiovascular research
ISSN: 1755-3245
Titre abrégé: Cardiovasc Res
Pays: England
ID NLM: 0077427

Informations de publication

Date de publication:
01 07 2020
Historique:
received: 04 03 2019
revised: 26 09 2019
accepted: 30 10 2019
pubmed: 7 11 2019
medline: 9 2 2021
entrez: 6 11 2019
Statut: ppublish

Résumé

Increased Ankyrin Repeat Domain 1 (ANKRD1) levels linked to gain of function mutations have been associated to total anomalous pulmonary venous return and adult cardiomyopathy occurrence in humans. The link between increased ANKRD1 level and cardiac structural and functional disease is not understood. To get insight into this problem, we have generated a gain of function ANKRD1 mouse model by overexpressing ANKRD1 in the myocardium. Ankrd1 is expressed non-homogeneously in the embryonic myocardium, with a dynamic nucleo-sarcomeric localization in developing cardiomyocytes. ANKRD1 transgenic mice present sinus venosus defect, which originates during development by impaired remodelling of early embryonic heart. Adult transgenic hearts develop diastolic dysfunction with preserved ejection fraction, which progressively evolves into heart failure, as shown histologically and haemodynamically. Transgenic cardiomyocyte structure, sarcomeric assembly, and stability are progressively impaired from embryonic to adult life. Postnatal transgenic myofibrils also present characteristic functional alterations: impaired compliance at neonatal stage and impaired lusitropism in adult hearts. Altogether, our combined analyses suggest that impaired embryonic remodelling and adult heart dysfunction in ANKRD1 transgenic mice present a common ground of initial cardiomyocyte defects, which are exacerbated postnatally. Molecular analysis showed transient activation of GATA4-Nkx2.5 transcription in early transgenic embryos and subsequent dynamic transcriptional modulation within titin gene. ANKRD1 is a fine mediator of cardiomyocyte response to haemodynamic load in the developing and adult heart. Increased ANKRD1 levels are sufficient to initiate an altered cellular phenotype, which is progressively exacerbated into a pathological organ response by the high ventricular workload during postnatal life. Our study defines for the first time a unifying picture for ANKRD1 role in heart development and disease and provides the first mechanistic link between ANKRD1 overexpression and cardiac disease onset.

Identifiants

pubmed: 31688894
pii: 5613185
doi: 10.1093/cvr/cvz291
doi:

Substances chimiques

ANKRD1 protein, human 0
GATA4 Transcription Factor 0
Gata4 protein, mouse 0
Homeobox Protein Nkx-2.5 0
Muscle Proteins 0
Nkx2-5 protein, mouse 0
Nuclear Proteins 0
Repressor Proteins 0
Protein Kinases EC 2.7.-
titin protein, mouse EC 2.7.11.1

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1458-1472

Commentaires et corrections

Type : CommentIn

Informations de copyright

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2019. For permissions, please email: journals.permissions@oup.com.

Auteurs

Nicoletta Piroddi (N)

Department of Experimental and Clinical Medicine, University of Florence, 50134 Florence, Italy.

Paola Pesce (P)

Department of Medicine, University of Padua, 35121 Padua, Italy.

Beatrice Scellini (B)

Department of Experimental and Clinical Medicine, University of Florence, 50134 Florence, Italy.

Stefano Manzini (S)

Department of Pharmacological and Biomolecular Sciences, University of Milan, 20133 Milan, Italy.

Giulia S Ganzetti (GS)

Department of Pharmacological and Biomolecular Sciences, University of Milan, 20133 Milan, Italy.

Ileana Badi (I)

Department of Biotechnology and Life Sciences, University of Insubria, 21100 Varese, Italy.
Division of Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, John Radcliffe Hospital, Oxford OX3 9DU, UK.

Michela Menegollo (M)

Department of Biomedical Sciences, University of Padua, 35121 Padua, Italy.

Virginia Cora (V)

Department of Biomedical Sciences, University of Padua, 35121 Padua, Italy.

Simone Tiso (S)

Department of Biomedical Sciences, University of Padua, 35121 Padua, Italy.

Raffaella Cinquetti (R)

Department of Biotechnology and Life Sciences, University of Insubria, 21100 Varese, Italy.

Laura Monti (L)

Department of Biotechnology and Life Sciences, University of Insubria, 21100 Varese, Italy.

Giulia Chiesa (G)

Department of Pharmacological and Biomolecular Sciences, University of Milan, 20133 Milan, Italy.

Steven B Bleyl (SB)

Department of Pediatrics, University of Utah, Salt Lake City, 84132 UT, USA.

Marco Busnelli (M)

Department of Pharmacological and Biomolecular Sciences, University of Milan, 20133 Milan, Italy.

Federica Dellera (F)

Department of Pharmacological and Biomolecular Sciences, University of Milan, 20133 Milan, Italy.

Daniele Bruno (D)

Department of Biotechnology and Life Sciences, University of Insubria, 21100 Varese, Italy.

Federico Caicci (F)

Department of Biology, University of Padua, 35121 Padua, Italy.

Annalisa Grimaldi (A)

Department of Biotechnology and Life Sciences, University of Insubria, 21100 Varese, Italy.

Roberto Taramelli (R)

Department of Biotechnology and Life Sciences, University of Insubria, 21100 Varese, Italy.

Lucia Manni (L)

Department of Biology, University of Padua, 35121 Padua, Italy.

David Sacerdoti (D)

Department of Medicine, University of Padua, 35121 Padua, Italy.

Chiara Tesi (C)

Department of Experimental and Clinical Medicine, University of Florence, 50134 Florence, Italy.

Corrado Poggesi (C)

Department of Experimental and Clinical Medicine, University of Florence, 50134 Florence, Italy.

Simonetta Ausoni (S)

Department of Biomedical Sciences, University of Padua, 35121 Padua, Italy.

Francesco Acquati (F)

Department of Biotechnology and Life Sciences, University of Insubria, 21100 Varese, Italy.

Marina Campione (M)

Department of Biomedical Sciences, University of Padua, 35121 Padua, Italy.
CNR-Neuroscience Institute, 35121 Padua, Italy.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male
Humans Meals Time Factors Female Adult

Classifications MeSH